Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2025; 17(12): 110621
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.110621
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.110621
Investigating radiotherapy’s impact on intestinal perforation risk in gastrointestinal tumor patients treated with bevacizumab
Wei-Mei He, Department of Pharmaceutical, Affiliated Hospital of Youjiang University of Ethnic Medicine, Baise 533000, Guangxi Zhuang Autonomous Region, China
Wen-Si Li, Department of Infirmary, Guilin Tourism University, Guilin 541006, Guangxi Zhuang Autonomous Region, China
Author contributions: He WM designed the research study; Li WS performed the research; and all authors thoroughly reviewed and endorsed the final manuscript.
Institutional review board statement: The research was reviewed and approved by Affiliated Hospital of Youjiang University of Ethnic Medicine, approval No. YYFY-LL-2023-60.
Informed consent statement: All research participants or their legal guardians provided written informed consent prior to study registration.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No other data available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wen-Si Li, Chief Pharmacist, Department of Infirmary, Guilin Tourism University, No. 26 Liangfeng Road, Yanshan District, Guilin 541006, Guangxi Zhuang Au
Received: July 1, 2025
Revised: August 7, 2025
Accepted: October 15, 2025
Published online: December 15, 2025
Processing time: 163 Days and 0.2 Hours
Revised: August 7, 2025
Accepted: October 15, 2025
Published online: December 15, 2025
Processing time: 163 Days and 0.2 Hours
Core Tip
Core Tip: This study investigates the risk of intestinal perforation in gastrointestinal tumor patients treated with radiotherapy combined with bevacizumab vs bevacizumab alone. While radiotherapy and bevacizumab are essential for managing advanced gastrointestinal cancers, both treatments can cause gastrointestinal complications, including perforation. The study compares the incidence of intestinal perforation and survival outcomes, aiming to inform clinical decision-making and enhance patient safety.